Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK?s*National Institute for Health and Care Excellence (NICE)*has*recommended*the expanded use of the Oncotype DX Breast Recurrence Score? test to more effectively target chemotherapy treatment for women who have hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), early-stage breast cancer involving up to three positive nodes and who have been through the menopause.
More...
Linear Mode
